US Edition
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
- On June 12, 2025, UCB revealed plans to invest $5 billion in establishing a cutting-edge biologics production site within the United States.
- UCB made this investment to address growing U.S. market demand and to reinforce its long-term commitment to innovation, healthcare, and economic contribution.
- The project is expected to generate approximately 300 long-term, specialized manufacturing positions and more than 500 construction roles, while UCB advances its expansion of contract manufacturing partnerships and assesses potential facility locations.
- CEO Jean-Christophe Tellier emphasized that this investment demonstrates UCB's expanding presence in the US and their commitment to delivering upcoming treatments to patients globally.
- This investment aims to ensure a resilient supply chain, support biomedical innovation, and deliver sustainable value for patients and communities in the United States.
13 Articles
13 Articles
The Belgian chemical and biopharmaceutical company multiplies investments. ...
Observer News Enterprise
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Committed to serve U.S. patients and deliver economic impact of approximately $5 billion, including creation of 300 U.S. direct high skilled jobs and more than 500 construction jobsScaling up U.S. based Contract Manufacturing Organization (CMO) partnerships to support the growth…
Biologics for Ulcerative Colitis: What Are the Pros and Cons?
Over the past 15 years, treatment options for ulcerative colitis (UC) , a type of inflammatory bowel disease, have expanded quite a bit. Among the most common options is a class of drugs called biologics . Biologics are derived from natural sources, such as human or animal genes or microorganisms, and are designed to act on the immune system, specifically the parts that play key roles in fueling inflammation.e60dc2a1-f33c-4a05-9b50-8e3e8e5976297…
19:00 To keep up with strong growth, Belgian pharmaceutical company UCB is investing $2 billion over the next six to seven years in a new production facility in the United States, its most important market...
Coverage Details
Bias Distribution
- 83% of the sources are Center
To view factuality data please Upgrade to Premium
